A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients-Reference-Cited by-同舟云学术

A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients

Published:2002-10-31 Issue:10 Volume:95 Page:2160-2168
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hussein Mohamad A.,Wood Laura,Hsi Eric,Srkalovic Gordan,Karam MaryAnn,Elson Paul,Bukowski Ronald M.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference44 articles.

1. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.

2. Plasma cell neoplasms. In: Cancer: principles and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven, 1997: 2344-2387.

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia;Science Translational Medicine;2023-05-17

2. Current approaches to management of newly diagnosed multiple myeloma;American Journal of Hematology;2022-03-10

3. Programmed cell death, redox imbalance, and cancer therapeutics;Apoptosis;2021-07-08

4. QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics;Current Treatment Options in Oncology;2019-05-25

5. A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma;International Journal of Hematology;2018-05-25